Fosamax and Osteonecrosis of the Jaw: Understanding the Link and Risk Factors

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy of Patient Safety and the Evolution of Drug Risk Awareness

Within general health and science communication, the legacy of patient safety has long emphasized the importance of understanding how routine medical interventions may carry unintended consequences. This foundational awareness, built over decades of public health education, has prepared both clinicians and lay audiences to consider that even widely prescribed treatments require ongoing scrutiny. As this heritage of vigilance extends into more specialized domains, a natural progression emerges: the need to examine specific pharmaceutical exposures and their potential links to adverse outcomes. In the context of mass production and widespread drug distribution, the transition from general health literacy to occupational and clinical exposure concerns becomes particularly salient. One such area of focused inquiry involves the relationship between bisphosphonate therapy—specifically Fosamax—and the risk of osteonecrosis of the jaw. While the general health context provides the framework for understanding medication side effects, the pivot toward exposure concern requires a shift in perspective: from population-level awareness to individual risk assessment in both clinical and occupational settings. This transition acknowledges that the same drug, when produced at scale and prescribed broadly, may present distinct considerations for patients and healthcare workers alike, thereby bridging the gap between general health knowledge and targeted exposure evaluation.

Bridging General Health Awareness to Specific Exposure Concerns

Building on the legacy of patient safety, the focus now narrows to a specific pharmaceutical agent: Fosamax (alendronate). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax. ONJ is characterized by exposed necrotic bone in the maxillofacial region that can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The condition has been reported in patients taking bisphosphonates, including Fosamax and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The clinical presentation of ONJ involves delayed healing of the jawbone following dental procedures, often with exposed bone that may become infected. Diagnosis is typically based on clinical examination and imaging, with a focus on identifying necrotic bone in the oral cavity.

Mechanistic Pathways and Evidence Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover and remodeling. In the jawbone, which has high metabolic activity and is subject to frequent microtrauma from chewing and dental procedures, this suppression may impair the healing response, leading to necrosis. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known risk, its occurrence in clinical trials was not significantly elevated compared to placebo, likely due to the rarity of the event.

Risk Factors and Epidemiological Data

A cohort study among cancer-free female patients aged 40-89 with or at risk for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702). This indicates that the risk of ONJ increases with longer exposure to bisphosphonates, but the absolute risk remains small. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Most patients had relief of symptoms after stopping the drug, and a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific warning under section 5.4 "Osteonecrosis of the Jaw" that describes the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label advises discontinuation of use if severe symptoms develop and notes that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also states that the optimal duration of use has not been determined, and for patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. The evidence shows that ONJ risk increases with longer duration of bisphosphonate use, and the condition can occur from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702). However, ONJ can also occur spontaneously without bisphosphonate use, and the absolute risk remains low (https://pubmed.ncbi.nlm.nih.gov/39400702). For patients who develop ONJ while on Fosamax, discontinuation of the drug may lead to symptom relief, and the risk diminishes after discontinuation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://pubmed.ncbi.nlm.nih.gov/39400702). Rechallenge with the same or another bisphosphonate may lead to recurrence of symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax use is associated with an increased risk of ONJ, particularly with longer duration of exposure and in the presence of other risk factors such as invasive dental procedures. The prescribing information provides warnings and recommendations for management, including discontinuation of treatment when appropriate. The absolute risk of ONJ in osteoporosis patients is low, but it increases with cumulative exposure.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it used?

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed necrotic bone in the maxillofacial region, often associated with tooth extraction or local infection. It is a recognized adverse effect of bisphosphonate use, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk increases with longer duration of exposure (https://pubmed.ncbi.nlm.nih.gov/39400702).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How common is ONJ in patients taking Fosamax for osteoporosis?

The absolute risk is low, approximately 0.05% after 5 years of use, but it increases with longer exposure. A cohort study found a threefold higher risk after 2-3 years and eightfold higher after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702).

What should I do if I develop symptoms of ONJ while on Fosamax?

Consult your healthcare provider. The prescribing information advises discontinuation of Fosamax if severe symptoms develop, and most patients experience relief after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.